• Media
  • Careers
  • Contacts
CBP - Pioneering and developing Bi-targeting XDC technologyCBPCBPCBP

Pioneering and developing Bi-targeting XDC technology

Contacts
  • Who We Are
    • About CBP
    • Our Culture
    • Leadership
    • Our History
  • Science & Innovation
    • Approach
    • Platforms
    • World of Bi-XDC
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Publications
  • For Patient
    • Patient Safety
    • Clinical Sites
    • Expanded Access Policy

Tag Archives: FDA

Author By adminPosted on February 23, 2025February 23, 2025

The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019

Suzhou, China, February 21, 2025 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration...
Read More
Author By adminPosted on October 12, 2024October 12, 2024

The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008

October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
Read More

Categories

  • News 26

Recent Posts

  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019February 23, 2025
  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008October 12, 2024
  • Coherent Biopharma’s CBP-1019 has received Orphan Drug Designation from the FDA for three indicationsJune 26, 2024
  • ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attentionJune 5, 2024
  • 【AACR 2024】Coherent Biopharma Announced Latest Pipeline CBP-8008 Preclinical Research ProgressApril 10, 2024

Archives

  • 2025 (1)
  • 2024 (5)
  • 2023 (6)
  • 2022 (4)
  • 2021 (3)
  • 2020 (4)
  • 2019 (1)
  • 2018 (2)

Meet CBP

  • Leadership
  • Our History
  • Our Culture

Science&Innovation

  • Approach
  • Platforms
  • World of Bi-XDC

Pipeline

  • Pipeline
  • Clinical Trials
  • Publications

For Patient

  • Patient Safety
  • Clinical Sites
  • Expanded Access Policy
Copyright © 2025 CBP  All rights reserved.